News & Events

News room

  • March 7, 2018
    Third iCardiac/ERT-Certified Site for Altasciences Clinical Research
    Altasciences Clinical Research announced today that its third clinical facility, Algorithme Pharma USA, in Fargo, North Dakota, has received its iCardiac/ERT Certification.
  • January 17, 2018
    Dr. Gaetano Morelli Joins Altasciences Clinical Research’s Medical Team
    Altasciences Clinical Research, a full-service provider focused on early stage clinical research with over twenty-five years of experience, proudly announces the addition of Dr. Gaetano Morelli to the Altasciences family.
  • November 29, 2017
    Vince & Associates, an Altasciences Company, Awarded a $9.5-Million, Five-Year Contract for Clinical Pharmacology Studies
    Vince & Associates Clinical Research, an Altasciences company, announced that it has been awarded a contract to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medications in humans.
  • October 18, 2017
    Altasciences Conducts Alcohol Drug-Drug Interaction Study for Amygdala Neurosciences Inc.
    Vince & Associates Clinical Research, an Altasciences company, announced today that they are working with Amygdala Neurosciences Inc. to conduct a Phase 1b, proof-of-concept, dose-ranging study to evaluate the safety of the co-administration of ascending doses of ANS-6637 and ethanol in healthy male alcohol drinkers.
  • October 11, 2017
    Vince & Associates, an Altasciences Company, to Evaluate Marijuana Compound in Clinical Trial
    Vince & Associates will conduct an inpatient clinical trial on the psychological effects of an active ingredient in marijuana — cannabidiol — in support of a federal collaboration seeking to better understand the abuse potential of the substance.
  • August 25, 2017
    Altasciences Clinical Research Offers Innovative Cannabis Research Solutions
    Altasciences is pleased to share that they are in the final stages of completing the world’s first safety and tolerability study on a cannabis extract being developed as a new chemical entity for approval by the FDA and Health Canada as a drug.